ÇмúÇà»ç
|
|
|
 |
|
|
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015³â Á¦27Â÷ Workshop °³ÃÖ °øÁö
|
ÀÛ¼ºÀÚ
|
°ü¸®ÀÚ
|
Date | 2015³â 03¿ù 03ÀÏ 10:26 | Hits | 5919 |
÷ºÎÆÄÀÏ
|
|
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015³â Á¦27Â÷ Workshop °³ÃÖ ¾È³»
¡á Çà»ç°³¿ä
Çà»ç¸í |
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015³â Á¦27Â÷ Workshop |
ÁÖÁ¦ |
"Translational approaches from nonclinical studies to clinical implementation (°¡Äª)" |
ÀϽà |
2015³â 5¿ù 20(¼ö) |
Àå¼Ò |
°æ±âÁß¼Ò±â¾÷Áö¿ø¼¾ÅÍ "±¤±³È¦" (1Ãþ) (ÁÖ¼Ò : °æ±âµµ ¼ö¿ø½Ã ¿µÅ뱸 ±¤±³·Î 107) |
´Ù¿î·Îµå |
°ø¹® - Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ Á¦27Â÷ ¿öÅ©¼¥ °³Ã־ȳ» |
¹®ÀÇ |
KSNS »ç¹«±¹ : Tel. 031) 706-2995 / E-mail. ksns@nonclinical.or.kr / ´ã´çÀÚ. Áö¼º¹Ì ¼±»ý´Ô |
¡á µî·Ï ¾È³»
- »çÀüµî·Ï ¾È³»
Çà»ç¸í |
¤ý 2015 Çѱ¹ºñÀӻ󿬱¸È¸ Á¦27Â÷ ¿öÅ©¼¥ |
µî·Ï±â°£ |
¤ý2015³â 4¿ù 29ÀÏ(È) 09½Ã ~ 5¿ù 18ÀÏ (¿ù) 18½Ã |
µî·Ï¹æ¹ý |
¤ý ¿¬±¸È¸ ȨÆäÀÌÁö (www.nonclinical.or.kr) ÇмúÇà»ç > »çÀüµî·Ï ¸Þ´º ÀÌ¿ë
¤ý ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ, »çÀüµî·ÏÀÌ °¡´ÉÇÕ´Ï´Ù. |
- µî·Ïºñ
µî·Ïºñ ±¸ºÐ |
»çÀüµî·Ï |
ÇöÀåµî·Ï
|
Á¤È¸¿ø |
50,000 ¿ø |
70,000 ¿ø |
Çлýȸ¿ø |
20,000 ¿ø |
40,000 ¿ø |
- »çÀüµî·Ïºñ : ÀÚ·áÁý, ¼ö·áÁõ, ½Äºñ Æ÷ÇÔ
- ¼¼±Ý°è»ê¼ ¹ß±Þ(ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇÒ °æ¿ì, ¿Â¶óÀÎ µî·Ï¶§ ¼¼±Ý°è»ê¼ ¹ßÇàÇà¿©ºÎ¸¦ üũÇϽðí, »ç¾÷ÀÚµî·ÏÁõ »çº»À» ¹Ýµå½Ã ÷ºÎ
- ÇöÀåµî·Ï ¹× Çлýµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ
|
- ¹«ÅëÀåÀÔ±Ý (°èÁÂÀÌü)
ÀԱݰèÁ |
¤ý ¿ì¸®ÀºÇà 1005-101-920320 ¢ß Å¥º£½ºÆ®ÄÁ¼³ÆÃ ºñÀӻ󿬱¸È¸ |
ÀԱݸ¶°¨ |
¤ý ~ 2015³â 5¿ù 18ÀÏ (¿ù) 18½Ã ±îÁö |
- ÀԱݽà ¹Ýµå½Ã "¼Ò¼Ó/¼º¸í" À» ±âÀÔÇϼ¼¿ä.
- ¹«ÅëÀå ÀÔ±Ý(°èÁÂÀÌü)ÀÌü ÈÄ, »ç¹«±¹¿¡¼ ÀÔ±ÝÀ» È®ÀÎÇÏ´Â ½Ã°£ÀÌ 1ÀÏÁ¤µµ ¼Ò¿ä µË´Ï´Ù.
- ½Å¿ëÄ«µå °áÁ¦´Â ºÒ°¡´É ÇÕ´Ï´Ù.
- ±âŸ µî·Ï °ü·Ã ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
Tel. 031-706-2995, E-mail ksns@nonclinical.or.kr, °íÁ¾È
|
¡á ÇÁ·Î±×·¥ ¾È³» (Draft / Ver.2015.05.01)
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸(KSNS) Á¦27Â÷ WORKSHOP Program (V2.0)
- ÁÖÁ¦: Translational approaches from nonclinical studies to clinical implementation
- ÀϽÃ: 2015³â 5¿ù 20ÀÏ (¼ö¿äÀÏ) 09:20 ~ 17:30
- Àå¼Ò: °æ±âÁß¼Ò±â¾÷Á¾ÇÕÁö¿ø¼¾ÅÍ(GSBC, ±¤±³Å×Å©³ë¹ë¸®³», °æ±âµµ ¼ö¿ø½Ã ¿µÅ뱸 ±¤±³·Î 107)
2015³â 5¿ù 20ÀÏ (¼ö)
|
Time |
PROGRAM |
09:20-09:50 |
Registration |
09:50-10:00 |
Opening (±èµ¿È¯ ȸÀå)
|
Session 1 |
Drug discovery and Development : Practice and Perspective (ÁÂÀå : ¾ÈÀü¼ºÆò°¡¿¬±¸¼Ò Â÷½Å¿ì ¹Ú»ç) |
10:00-10:40 |
ºñÀÓ»ó½ÃÇè °á°ú·ÎºÎÅÍ ÀÓ»ó ÃÊȸ¿ë·® ¼³Á¤ : FDA and EMEA guideline (°Ç¾ç´ë, ±èµ¿È¯ ±³¼ö) |
10:40-11:20 |
TEW-7197, An ALK5 inhibitor: From non-clinical studies to US FDA IND (¸ÞµåÆÑÅä, ÇÏÀÏÈ£ ¹Ú»ç) |
11:20-12:00 |
Pharmacokinetics with biologic - An industry prospective into best practices for the development and validation of ligand binding assays
to support biosimilar programs (Dr. Rashell Kinard, MPI) |
12:00-12:45 |
Luncheon symposium: ¿À¼Û÷º¹´ÜÁöÀÇ ±¹°¡Àû ½Å¾à°³¹ßÁö¿øÃ¼°è (Sponsor: ¿À¼Û÷´ÜÀÇ·á»ê¾÷ÁøÈïÀç´Ü) |
12:45-13:30 |
Booth Exhibition & Coffee Break
|
Session 2 |
µ¶¼ººÐ°ú (ÁÂÀå : ÇÑÈ, °í¿ì¼® ¹Ú»ç)
Issues & Solutions in Toxicity Studies |
¾àµ¿·ÂÇкаú (ÁÂÀå : µ¿¾Æ ST, ½ÉÇöÁÖ ¹Ú»ç)
PK studies related with clinical dose |
¾àÈ¿¾à¸®ºÐ°ú (ÁÂÀå : Çö´ë¾àǰ, ±è´ëÈÆ ¹Ú»ç)
Efficacy Evaluation for Key Therapeutic Areas |
13:30-14:10 |
Current Trends in Genetic Toxicology Testing
(KIT, ±èÁö¿µ ¼±ÀÓ¿¬±¸¿ø) |
ºñÀÓ»ó ÀÚ·áÀÇ ¸ðµ¨¸µ/½Ã¹Ä·¹À̼ÇÀ» ÅëÇÑ FIH ¿ë·® ¿¹ÃøÀÇ »ç·Ê
(ÀÓµ¿¼® ±³¼ö, °¡Å縯´ë) |
Anti-diabetic effect of amorphastilbol by increasing insulin sensitivity
(±è¿ë±â ±³¼ö, ¼÷¸í¿©´ë) |
14:10-14:50 |
º¹ÇÕÁ¦ µ¶¼º½ÃÇèÀÇ À̽´ ¹×
Àü·«Àû solution
(À̱ÔÇ× ¹Ú»ç, Çѹ̾àǰ) |
ÀüÀÓ»ó ½ÃÇè °á°ú¸¦ ÀÌ¿ëÇÑ Human efficacious dose projection
(Á¤¼ö¿ë ¼ö¼®¿¬±¸¿ø, À¯ÇѾçÇà) |
¾ËÃ÷ÇÏÀÌ¸Ó °ü·Ã ¾à¹° °³¹ßÀ» À§ÇÑ ºñÀÓ»ó
Á¢±Ù¹ý
(Å©·Î¿£¸®¼Ä¡ Áø½ÂÇÏ ¹Ú»ç) |
14:50-15:30 |
»ýü¿µ»ó ¹× ¹Ì¼¼¼ö¼úÀ» ÅëÇÑ ½Å¾à°³¹ß¿¡ ÀÖ¾î
À¯È¿¼º/¾ÈÀü¼º Æò°¡
(±è»ó±Õ ¹Ú»ç, ´ë±¸°æºÏ÷º¹´ÜÁö) |
Optimal clinical dose-finding strategies: Translational preclinical PK, PD, and efficacy analysis of orally selective EGFR mutant inhibitor
(ÀÌ¿µ¹Ì ¹Ú»ç, Çѹ̾àǰ) |
A biomarker as a necessary factor in development of targeted agent for cancer treatment
(Áøµ¿ÈÆ ±³¼ö, ¿ï»êÀÇ´ë) |
15:30-16:00 |
Booth Exhibition & Coffee Break |
Session 3 |
Drug discovery and Development: Case Studies (ÁÂÀå : ÃÖ¿¬½Ä ±³¼ö, Çѱ¹Æú¸®ÅØ´ëÇÐ) |
16:00-16:40 |
Â÷¼¼´ë ÁøÅë¼Ò¿°Á¦ ¾Æ¼¿·º½ºÀÇ °³¹ß (Å©¸®½ºÅ»Áö³ë¹Í½º, ³ë¼º±¸ ¹Ú»ç) |
16:40-17:20 |
A novel therapeutic DNA vaccine against persistent human papillomavirus infection (Á¦³Ø½Å, ÁøÇöŹ ¹Ú»ç) |
17:20-17:30 |
Closing (ÀÌ»óÈ£ ºÎȸÀå)
|
# »ó±â ÇÁ·Î±×·¥Àº ¿¬ÀÚ µîÀÇ »çÁ¤À¸·Î º¯µ¿ ¼ö ÀÖ½À´Ï´Ù.
¡á °æ±âÁß¼Ò±â¾÷Á¾ÇÕÁö¿ø¼¾ÅÍ "±¤±³È¦" ã¾Æ¿À½Ã´Â ±æ
ÁÖ¼Ò |
°æ±âµµ ¼ö¿ø½Ã ¿µÅ뱸 ±¤±³·Î 107, °æ±âÁß¼Ò±â¾÷Á¾ÇÕÁö¿ø¼¾ÅÍ "±¤±³È¦" (1Ãþ)
- [³×À̹ö Áöµµ]·Î À§Ä¡ È®ÀÎ ¹× ±³Åë Âü°í :  |
±³ÅëÆí ¾È³» |
°æ±âÁß¼Ò±â¾÷Á¾ÇÕÁö¿ø¼¾ÅÍ È¨ÆäÀÌÁö ³» [ ¿À½Ã´Â ±æ ] ¸Þ´º Âü°í :  |

|
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015³â Á¦27Â÷ Workshop ÇùÂù ¸ðÁý
(·±Ãµ¼¼¹Ì³ª, ºÎ½º, ±¤°í)
1. ±Í»çÀÇ ¹«±ÃÇÑ ¹ßÀüÀ» ±â¿øÇÏ¿À¸ç, Ç×»ó ÀúÈñ Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸¿¡ °ü½ÉÀ» °¡Á®Áֽɿ¡ ±íÀÌ °¨»çµå¸³´Ï´Ù.
2. Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸¿¡¼ ÁÖ°üÇÏ´Â Á¦27Â÷ WorkshopÀ» 2015³â 05¿ù 20ÀÏ(¼ö) °æ±â Áß¼Ò±â¾÷ Á¾ÇÕÁö¿ø¼¾ÅÍ ±¤±³È¦¿¡¼ "Translational approaches from nonclinical studies to clinical implementation (°¡Äª)" À̶õ ÁÖÁ¦·Î °³ÃÖÇϰíÀÚ ÇÕ´Ï´Ù. ¼º°øÀûÀÎ ÇмúÇà»ç °³ÃÖ¸¦ À§ÇÏ¿© ±Í ±â°üÀÇ ºÎ½º ¹× ±¤°í ÇùÂùÀ» ¿äû µå¸®¿À´Ï Àû±ØÀûÀÎ Âü¿© ºÎŹ µå¸³´Ï´Ù. ¶ÇÇÑ, ±Í»çÀÇ °ü°èÀÚ ºÐµé²²¼µµ ÇмúÇà»ç¿¡ Âü¼®ÇÏ½Ã¾î ±Í»ç¿¡ µµ¿òÀÌ µÉ human networking°ú Çмú±³·ù¸¦ ÇÒ ¼ö ÀÖµµ·Ï ÇùÁ¶ÇÏ¿© ÁÖ½Ã¸é °¨»çÇϰڽÀ´Ï´Ù.
- ´Ù À½ -
Çà»ç¸í |
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015³â Á¦27Â÷ Workshop |
ÁÖÁ¦ |
"Translational approaches from nonclinical studies to clinical implementation (°¡Äª)" |
ÀϽà |
2015³â 05¿ù 20(¼ö) 09:20~17:30 |
Àå¼Ò |
°æ±âÁß¼Ò±â¾÷Á¾ÇÕÁö¿ø¼¾ÅÍ ±¤±³È¦, Çõ½Å½Ç, Èñ¸Á½Ç |
ÇùÂù³»¿ë |
1) ·±Ãµ¼¼¹Ì³ª(ºÎ½º/±¤°í ¹× µµ½Ã¶ôºñ¿ë Æ÷ÇÔ): \5,000,000 (VATº°µµ) / Çмú´ëȸ Âü°¡ºñ 5¸í ¹«·á
* 20(¼ö) Á¡½É½Ã°£(12:00~13:00) / ½Ä»çÀοøÀº »çÀüµî·Ï ¸¶°¨ ÈÄ Å뺸 (2014³â ¾à 180¸í)
2) ºÎ½º(±¤°í Æ÷ÇÔ): \2,000,000 (VATº°µµ)
* ÇùÂù¾÷ü °ü°èÀÚ 2¸í¿¡ ÇÑÇÏ¿© Çмú´ëȸ Âü°¡ºñ ¹«·á
* ¼Ò¿¬È¸Àå¿¡ 2X2 ¹ÌÅÍ Å©±âÀÇ ºÎ½º ¼³Ä¡ °¡´É /ºÎ½º ´ç Å×À̺í 1°³ ¹× ÀÇÀÚ 2°³ Á¦°ø
* ºÎ½º¼³Ä¡¿Í °ü·Ã À¯ÀÇ»çÇ× ¹× Áغñ»çÇ×Àº Ãß ÈÄ °øÁö
3) ±¤°í(ÀÚ·áÁý): \1,000,000 (VATº°µµ) / Çмú´ëȸ Âü°¡ºñ 1¸í ¹«·á |
¸¶°¨ÀÏÀÚ |
2015³â 04¿ù 30ÀÏ(¸ñ)
* ·±Ãµ¼¼¹Ì³ª ¹× ºÎ½ºÀÇ °æ¿ì, ¼±Âø¼ø ¸¶°¨ (¼³Ä¡ À§Ä¡´Â º°µµ·Î Ãß÷ÁøÇà/Ãß÷ÀÏÁ¤ ÃßÈÄ Å뺸) |
ÀԱݰèÁ |
¿ì¸®ÀºÇà 1005-101-920320 ¢ßÅ¥º£½ºÆ®ÄÁ¼³ÆÃºñÀӻ󿬱¸È¸ |
°ü·Ã°ø¹® |
°ø¹® ´Ù¿î·Îµå :
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015 Á¦27Â÷ Workshop ÇùÂù ¸ðÁý (·±Ãµ¼¼¹Ì³ª, ºÎ½º, ±¤°í) |
¹®ÀÇ |
ÀÌ ¿Ü ±¤°íÇùÂù°ú °ü·ÃÇØ ±Ã±ÝÇϽŠ»çÇ×Àº KSNS »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
KSNS »ç¹«±¹ : Tel. 031) 706-2995 / E-mail. ksns@nonclinical.or.kr / ´ã´çÀÚ. °íÁ¾È |
|
|
|
 |
|
|